Know Cancer

or
forgot password

A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer


Inclusion Criteria:



- Histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma

- Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma

- 18 years of age or older

- Progressive prostate cancer as defined by the presence of one or more of the
following despite castrate levels of testosterone (testosterone <50 ng/dL):

1. Progressive tumor lesions (changes in the size of lymph nodes or parenchymal
masses on physical examination or X-ray and CT scan or MRI)

2. Progressive bone metastasis (presence of new lesion(s) on a bone scan)

3. Progressive PSA levels (as defined in Section 3.6.1)

- Subjects who have received an anti-androgen must have shown progression of disease
following discontinuation of the anti-androgen

- Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy
for the duration of the trial unless surgically castrate

- Agree to use an effective barrier method of contraception.

Exclusion criteria:

- Testosterone >50 ng/dL

- Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing

- Use of PC-SPES within 4 weeks of dosing

- Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing

- Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks
of dosing

- Prior monoclonal antibody administration, including Prostascint®

- Peripheral neuropathy of > Grade 2, as defined by the NCI Common Toxicity Criteria
for Adverse Events (NCI CTCAE)

- History of CNS metastasis, including incompletely treated epidural disease

- History of Hepatitis B or C

- History of seizure disorder requiring active treatment and/or stroke

- History of HIV infection

- Platelet count <100,000/mm3

- Absolute neutrophil count (ANC) <1,500/mm3

- Hematocrit <27 percent

- Abnormal coagulation profile (elevated PT, and/or INR, PTT)

- Serum creatinine >2.0 mg/dL, or creatinine clearance <60 mL/min if serum creatinine
>2.0 mg/dL

- AST or ALT >1.5 x ULN

- Bilirubin (total) >1.25 x ULN

- Serum calcium >12.5 mg/dL

- Active serious infection not controlled by antibiotics

- Active angina pectoris or NY Heart Association Class III-IV heart disease

- Karnofsky Performance Status <60%

- Life expectancy <6 months

- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
hematological organ systems that might preclude completion of this study or interfere
with determination of causality of any adverse effects experienced in this study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

M59102-051

NCT ID:

NCT00070837

Start Date:

October 2003

Completion Date:

October 2004

Related Keywords:

  • Prostatic Neoplasms
  • Neoplasms
  • Prostatic Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Weill Medical College of Cornell University/ New York Presbyterian HospitalNew York, New York  10021
Duke University Medical Center, Box 3532Durham, North Carolina  27710
Cleveland Clinic, Taussig Cancer CenterCleveland, Ohio  44195